跳至主要内容
临床试验/IRCT20151227025726N19
IRCT20151227025726N19已完成2 期

Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients with the age of 18 years and older
  • Patients who were initiated on oral or intravenous voriconazole for proven, probable, or possible invasive aspergillosis

排除标准

  • History of allergy or severe reaction to azoles
  • Aspergilloma or allergic bronchopulmonary aspergillosis
  • Concomitant use of carbamazepine, efavirenz, rifampin, sirolimus or Ergot alkaloids
  • Chronic invasive aspergillosis with duration of symptoms for more than 4 weeks
  • Severe liver dysfunction (total bilirubin, , alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) more than 3 times the upper limit of normal)
  • Receiving combination of antifungal therapy

研究者

相似试验